Patients with Diabetes may expect to receive alternative therapy soon – a study review by BIOMEDICA CRO team
Scientists at the University of Geneva (UNIGE) have been working for several years on an alternative therapy for patients with Diabetes based on the S100A9 protein.
“To develop a drug, however, we had to understand how this protein works precisely and demonstrate its effectiveness in animal models”, – said Giorgio Ramadori, research associate in Professor Coppari’s lab and lead author of the study.
The team first set out to decipher the mode of action of S100A9 in diabetic mice and discovered that this protein acts in the liver. The next step was examining the blood of diabetic people arriving at the emergency room with severe insulin deficiency.
“A slight but insufficient natural increase in S100A9 is detected,” explains Giorgio Ramadori. “Therefore, additional administration of S100A9 is expected to enhance this compensatory mechanism.”
Now researchers plan to test their drug in conjunction with low doses of insulin, but do not rule out the possibility of administering the S100A9 protein alone in the future, in specific conditions.
Please find more information on the University of Geneva website.
Biospecimen CRO services – BIOMEDICA CRO is here to provide human biospecimens for your research!
BIOMEDICA CRO provides both prospective and retrospective collections of the numerous human biospecimen types and associated clinical data since 2017.
Patients with various diseases may become donors for your studies, including diabetic people. Due to our business model and direct way of communication with Primary Investigators you will get the highest quality of human biospecimen and insurance that all project details are followed.
For instance, we can provide the next types of biospecimens from donors with Type 1 and Type 2 Diabetes:
- Whole blood;
- Single/double spun plasma;
- Serum;
- Buffy coat;
- PBMCs;
- Urine;
- Stool;
- Saliva, etc.
BIOMEDICA CRO operates within the strictest ethical guidelines.
It means that all clinical materials are exclusively obtained after approval of the Institutional Review Board or the Independent Ethical Committee (IRB/IEC) as well as all donors are mandatory consented and signed the Individual Consent Form.
Please email us to start our collaboration: office@biomedica-cro.com / LinkedIn.
